Justin M Oldham1, Shwu-Fan Ma1, Fernando J Martinez2, Kevin J Anstrom3, Ganesh Raghu4, David A Schwartz5, Eleanor Valenzi1, Leah Witt1, Cathryn Lee1, Rekha Vij1, Yong Huang1, Mary E Strek1, Imre Noth1. 1. 1 Section of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Chicago, Chicago, Illinois. 2. 2 Department of Internal Medicine, Weill Cornell Medical School, New York City, New York. 3. 3 Duke Clinical Research Institute, Duke University, Durham, North Carolina. 4. 4 Division of Pulmonary and Critical Care Medicine, Department of Medicine, The University of Washington Medical Center, Seattle, Washington; and. 5. 5 Department of Medicine, The University of Colorado, Denver, Colorado.
Abstract
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology. The genes TOLLIP and MUC5B play important roles in lung host defense, which is an immune process influenced by oxidative signaling. Whether polymorphisms in TOLLIP and MUC5B modify the effect of immunosuppressive and antioxidant therapy in individuals with IPF is unknown. OBJECTIVES: To determine whether single-nucleotide polymorphisms (SNPs) within TOLLIP and MUC5B modify the effect of interventions in subjects participating in the Evaluating the Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis (PANTHER-IPF) clinical trial. METHODS: SNPs within TOLLIP (rs5743890/rs5743894/rs5743854/rs3750920) and MUC5B (rs35705950) were genotyped. Interaction modeling was conducted with multivariable Cox regression followed by genotype-stratified survival analysis using a composite endpoint of death, transplantation, hospitalization, or a decline of ≥ 10% in FVC. MEASUREMENTS AND MAIN RESULTS: Significant interaction was observed between N-acetylcysteine (NAC) therapy and rs3750920 within TOLLIP (P interaction = 0.001). After stratifying by rs3750920 genotype, NAC therapy was associated with a significant reduction in composite endpoint risk (hazard ratio, 0.14; 95% confidence interval, 0.02-0.83; P = 0.03) in those with a TT genotype, but a nonsignificant increase in composite endpoint risk (hazard ratio, 3.23; 95% confidence interval, 0.79-13.16; P = 0.10) was seen in those with a CC genotype. These findings were then replicated in an independent IPF cohort. CONCLUSIONS: NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology. The genes TOLLIP and MUC5B play important roles in lung host defense, which is an immune process influenced by oxidative signaling. Whether polymorphisms in TOLLIP and MUC5B modify the effect of immunosuppressive and antioxidant therapy in individuals with IPF is unknown. OBJECTIVES: To determine whether single-nucleotide polymorphisms (SNPs) within TOLLIP and MUC5B modify the effect of interventions in subjects participating in the Evaluating the Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis (PANTHER-IPF) clinical trial. METHODS: SNPs within TOLLIP (rs5743890/rs5743894/rs5743854/rs3750920) and MUC5B (rs35705950) were genotyped. Interaction modeling was conducted with multivariable Cox regression followed by genotype-stratified survival analysis using a composite endpoint of death, transplantation, hospitalization, or a decline of ≥ 10% in FVC. MEASUREMENTS AND MAIN RESULTS: Significant interaction was observed between N-acetylcysteine (NAC) therapy and rs3750920 within TOLLIP (P interaction = 0.001). After stratifying by rs3750920 genotype, NAC therapy was associated with a significant reduction in composite endpoint risk (hazard ratio, 0.14; 95% confidence interval, 0.02-0.83; P = 0.03) in those with a TT genotype, but a nonsignificant increase in composite endpoint risk (hazard ratio, 3.23; 95% confidence interval, 0.79-13.16; P = 0.10) was seen in those with a CC genotype. These findings were then replicated in an independent IPF cohort. CONCLUSIONS:NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.
Authors: Kim M Smits; Jan S Schouten; Luc J Smits; Foekje F Stelma; Patty Nelemans; Martin H Prins Journal: J Clin Epidemiol Date: 2005-04-18 Impact factor: 6.437
Authors: C Pérez-Giraldo; A Rodríguez-Benito; F J Morán; C Hurtado; M T Blanco; A C Gómez-García Journal: J Antimicrob Chemother Date: 1997-05 Impact factor: 5.790
Authors: Yi-Wei Tang; Joyce E Johnson; Philip J Browning; Roberto A Cruz-Gervis; Angela Davis; Barney S Graham; Kenneth L Brigham; John A Oates; James E Loyd; Arlene A Stecenko Journal: J Clin Microbiol Date: 2003-06 Impact factor: 5.948
Authors: Jürgen Behr; Michael Kreuter; Marius M Hoeper; Hubert Wirtz; Jens Klotsche; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Winfried Randerath; Dirk Skowasch; F Joachim Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Rudolf Maria Huber; Claus Neurohr; Martin Schwaiblmair; Martin Kohlhäufl; Gert Höffken; Matthias Held; Andrea Koch; Thomas Bahmer; David Pittrow Journal: Eur Respir J Date: 2015-04-02 Impact factor: 16.671
Authors: Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth Journal: Am J Respir Crit Care Med Date: 2017-07-15 Impact factor: 21.405
Authors: Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405
Authors: Jonathan A Kropski; Lisa R Young; Joy D Cogan; Daphne B Mitchell; Lisa H Lancaster; John A Worrell; Cheryl Markin; Na Liu; Wendi R Mason; Tasha E Fingerlin; David A Schwartz; William E Lawson; Timothy S Blackwell; John A Phillips; James E Loyd Journal: Am J Respir Crit Care Med Date: 2017-06-01 Impact factor: 21.405
Authors: Paolo Cameli; Alfonso Carleo; Laura Bergantini; Claudia Landi; Antje Prasse; Elena Bargagli Journal: Inflammation Date: 2020-02 Impact factor: 4.092